Exploring the Impact of Cemiplimab and Pembrolizumab in Cutaneous Squamous Cell Carcinoma With Shaheer Khan, DO

Recently, Oncology Data Advisor spoke with Dr. Shaheer Khan, an Assistant Professor of Medicine at Columbia University Irving Medical Center, in honor of Skin Cancer Awareness Month. Dr. Khan shares the promising results of two recent trials of cemiplimab and pembrolizumab for cutaneous squamous cell carcinoma, explains future directions in the treatment of patients who are ineligible for immunotherapy, and offers advice for members of the multidisciplinary cancer care team who are treating patients with this disease.  

Continue reading

Navigating the Selection of Immunotherapy in Metastatic Melanoma With Benjamin Izar, MD

Recently, the FDA approved the combination of relatlimab plus nivolumab for patients with unresectable or metastatic melanoma. However, many challenges remain in the selection of patients who will benefit from these agents and in determining alternative options for those who are ineligible for the combination. In this interview in honor of Melanoma Awareness Month, Dr. Benjamin Izar discusses the risk-benefit balance of immunotherapy selection and offers advice for clinicians in how to choose th...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.